Spectrum_Autism

some of the existing data involves single cannabinoid compounds rather full spectrum cannabinoids, and the results may vary based on the dosage, blend, route of administration, etc

data with epidiolex in rare forms of epilepsy is with a single compound CBD;

data with CBDV is using a single compound that does not contain THC

there is some data with full spectrum 20:1 ratio CBD:THC

it is unclear whether or not THC is necessary or helpful, and whether or not an entourage effect is helpful or associated with additional side effects

There is a real risk that individuals who are prone to psychosis can have an exacerbation of psychosis with THC.

Therefore, CBD or CBDV that do not contain THC would be a safer alternative

gabaergic mechanisms are involved in cortical inhibition and GABA enhancing approaches may also decrease epileptiform activity and decrease irritability and repetitive behaviors.

we are studying whether CBDV which impacts excitation/ihibition balance may improve irritability and disruptive behaviors, improve repetitive and compulsive behaviors and improve social communication

there is a need for additional studies to determine benefits and risks for a range of different compounds, combination of compounds, dosing, optimal age ranges, particular behavioral symptoms, etc

if data is promiising in ASD, then there may be relevance for other neurodevelopmental disorders